News GSK boosts anti-infectives pipeline with Scynexis antifungal Last year, GSK said it was planning to invest a cool £1 billion in infectious d
News Rezzayo antifungal okayed as Candida auris rings alarm bells Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
News EMA starts review of Cidara's candidiasis therapy rezafungin The EU regulator has started its review of Cidara Therapeutics' once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
